Lisata Therapeutics Inc Investor Relations Material
Latest events
Q4 2023
Lisata Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Lisata Therapeutics Inc
Access all reports
Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing cellular therapies to reverse disease, promote regeneration and halt disease progression. Its product candidates include HONEDRA, a cell therapy product candidate that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease; AB1250-H, an investigational drug product candidate for acute myocardial infarction (AMI) patients who have undergone percutaneous coronary intervention (PCI); and VB6100, an investigational gene therapy product candidate designed to treat demyelinating disorders such as multiple sclerosis
Key slides for Lisata Therapeutics Inc
Q4 2023
Lisata Therapeutics Inc
Q4 2023
Lisata Therapeutics Inc
Latest articles
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
John Elkann: Leading Stellantis, Ferrari, and Exor to New Heights
As the Chairman of Stellantis and Ferrari and CEO of Exor, John Elkann is arguably the most influential person in the global automotive sector.
26 Mar 2024
Ticker symbol
Country
🇺🇸 United States